Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168891 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL1746181 | 0.81 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL873427 | 0.80 | — | — | |
| SCHEMBL14474333 | 0.78 | — | — | |
| SCHEMBL20878691 | 0.78 | — | — | |
| SCHEMBL197402 | 0.78 | — | — | |
| SCHEMBL11652607 | 0.77 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL3711992 | 0.77 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL28249091 | 0.77 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| Propionic Acid SCHEMBL72834 | 0.75 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277884-B1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-23 | — | — | EP | disclosed |
| US-9115165-B2 | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-08-25 | — | — | US | disclosed |
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2011-09-15 | — | — | US | disclosed |
| EP-2277884-A1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-01-26 | — | — | EP | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| CN-1046529-A | Carbostyril derivative | OTSUKA PHARMA CO LTD (JP) | 1990-10-31 | — | — | CN | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | DHPS, TBCA, ANTXR2 | SLC6A2 4703/4885SLC6A4 4788/4885SLC6A3 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.